What is Bone Biologics?
Founded in 2004 by a consortium of distinguished professors from the University of California and Osaka University, alongside a USC surgeon, Bone Biologics operates at the intersection of biotechnology and surgical innovation. The company functions as a specialized spin-off of the Musculoskeletal Transplant Foundation, focusing on the development of its patented UCB-1 platform technology. This technology, exclusively licensed from UCLA, is engineered to facilitate superior bone growth, having demonstrated efficacy in large animal models that surpass current clinical standards. By targeting the broad orthobiologics market, the firm aims to redefine outcomes for surgical procedures requiring complex bone repair, positioning itself as a critical player in the regenerative medicine landscape.
How much funding has Bone Biologics raised?
Bone Biologics has raised a total of $16.1M across 1 funding round:
Stock Offering
$16.1M
Stock Issuance/Offering (2014): $16.1M, investors not publicly disclosed
Key Investors in Bone Biologics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Bone Biologics?
With the recent capital injection, Bone Biologics is poised to accelerate the clinical validation and commercialization of the UCB-1 platform. The company's strategic roadmap involves transitioning from successful animal model studies to broader human clinical applications, aiming to address unmet needs in orthopedic surgery. As the firm scales its operations, the focus will likely remain on optimizing the delivery of its regenerative technology to ensure it becomes a standard-of-care solution. Investors and industry stakeholders are closely monitoring the company's ability to translate its academic research into scalable, market-ready medical products that offer improved patient outcomes in bone regeneration procedures.
See full Bone Biologics company page
